Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Lenvatinib (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Regorafenib (Primary) ; Rivoceranib (Primary) ; Sorafenib (Primary)
Indications Biliary cancer; Carcinoma; Liver cancer
Focus Therapeutic Use

27 Mar 2023 Planned number of patients changed from 2000 to 3000.
27 Mar 2023 Planned End Date changed from 1 Sep 2022 to 31 Dec 2025.
27 Mar 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Oct 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com